Because of the high cost of clinical trials and the marketing infrastructure need to sell antibiotics, Synereca will establish partnerships with pharmaceutical companies to develop and commercialize a RecA/antibiotic combination product.

Partnering with Synereca offers a pharmaceutical company the opportunity to develop a combination product that will either extend or revive its antibiotic franchise that is at risk because of patent expiration or because bacterial resistance is rendering its antibiotic ineffective.